| __timestamp | Amicus Therapeutics, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 612613000000 |
| Thursday, January 1, 2015 | 47269000 | 650773000000 |
| Friday, January 1, 2016 | 71151000 | 619061000000 |
| Sunday, January 1, 2017 | 88671000 | 628106000000 |
| Monday, January 1, 2018 | 127200000 | 717599000000 |
| Tuesday, January 1, 2019 | 169861000 | 964737000000 |
| Wednesday, January 1, 2020 | 156407000 | 875663000000 |
| Friday, January 1, 2021 | 192710000 | 886361000000 |
| Saturday, January 1, 2022 | 213041000 | 997309000000 |
| Sunday, January 1, 2023 | 275270000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Takeda Pharmaceutical Company Limited, a global leader, and Amicus Therapeutics, Inc., a rising star, present a fascinating study in contrasts. From 2014 to 2023, Takeda's Selling, General, and Administrative (SG&A) expenses have consistently dwarfed those of Amicus, reflecting its expansive global operations. In 2023, Takeda's SG&A expenses reached a staggering 1.05 trillion yen, marking a 72% increase from 2014. Meanwhile, Amicus, with its focused niche strategy, saw its SG&A expenses grow by over 1,200% during the same period, peaking at 275 million dollars in 2023. This divergence highlights the varied approaches to growth and market penetration. While Takeda leverages its scale, Amicus invests heavily in strategic marketing and administration to carve out its market share. Missing data for 2024 suggests ongoing financial adjustments.
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Sanofi or Takeda Pharmaceutical Company Limited
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.